Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological confirmation of recurrent or metastatic HNSCC~* Measurable disease as defined by RECIST v1.1~* PD-L1 positive~Exclusion Criteria:~* Diagnosis of recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary histology; or salivary gland or non-squamous histologies (e.g. mucosal melanoma)~* Disease amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)~* Prior systemic anti-cancer therapy (use of chemotherapeutic agents, targeted small molecules, immunotherapy, or monoclonal antibodies) for the treatment of recurrent or metastatic HNSCC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADU-S100 and pembrolizumab (Type: EXPERIMENTAL): All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.

Based on this trial design, predict the completion outcome and termination type (if applicable).